GlassScriptPhysician profile
Manali A Shendrikar
NPI 1831131622
$6,369.26
in general payments reported to CMS, 2019-2025
43 companies · $2,101 in 2025
The $2,101 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $165 · 2021: $155 · 2022: $657 · 2023: $1,209 · 2024: $1,623 · 2025: $2,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,932.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $901.51 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $608.01 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $566.53 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $527.60 | 2019-2025 | Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $476.63 | 2024-2025 | |
| Abbvie INC. | $389.10 | 2022-2025 | Synthroid |
| Novartis Pharmaceuticals Corporation | $331.62 | 2022-2025 | |
| Pfizer INC. | $329.61 | 2020-2025 | |
| Bausch Health US, LLC | $231.84 | 2024-2025 | Aplenzin, Wellbutrin |
| Idorsia Pharmaceuticals US INC | $215.62 | 2022-2024 | Quviviq |
| Glaxosmithkline, LLC. | $193.47 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Cochlear Americas | $159.81 | 2025 | Osia Osi300 Implant, Baha, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Harmony Biosciences LLC | $124.28 | 2025 | |
| Gilead Sciences, INC. | $123.74 | 2023 | Descovy |
| Almatica Pharma LLC | $120.28 | 2023-2024 | Loreev Xr, Gralise, Teriparatide |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $104.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $86.00 | 2025 | Vyepti |
| Astellas Pharma US INC | $79.61 | 2022-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $75.75 | 2022 | |
| Eisai INC. | $72.79 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.77 | 2021-2024 | Tradjenta, Jardiance, Synjardy |
| Axsome Therapeutics, INC. | $50.80 | 2025 | Symbravo |
| Boston Scientific Corporation | $50.01 | 2023 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.77 | 2024 | Xifaxan |
| Ibsa Pharma INC. | $39.33 | 2022-2025 | Tirosint, Licart, Flector |
| Cranial Technologies, INC | $35.88 | 2023-2025 | Doc Band |
| Phadia US INC. | $32.06 | 2023 | Immunocap |
| Takeda Pharmaceuticals U.S.A., INC. | $25.64 | 2020 | |
| Biotronik Nro, INC. | $25.17 | 2024 | Prospera |
| Intra-Sana Laboratories | $24.51 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Scilex Pharmaceuticals INC. | $24.35 | 2023 | Ztlido |
| Therapeuticsmd, INC. | $23.44 | 2021 | |
| Sumitomo Pharma America, INC. | $20.91 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $20.83 | 2019 | |
| Amarin Pharma, INC. | $20.77 | 2019 | |
| Impel Pharmaceuticals INC. | $20.41 | 2022 | |
| Genentech USA, INC. | $19.71 | 2020 | |
| Amag Pharmaceuticals, INC. | $19.07 | 2019 | |
| Janssen Scientific Affairs, LLC | $18.04 | 2020 | |
| Currax Pharmaceuticals LLC | $17.09 | 2024 | Contrave |
| Hologic Sales and Service, LLC | $16.98 | 2025 | Aptima, Thinprep 2000 Processor |
| Kowa Pharmaceuticals America, INC. | $15.72 | 2022 | |
| Abbott Laboratories | $15.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manali Shendrikar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.